GR0245766S12S
Cedars-Sinai Medical Center will serve as an enrolling site for the proposed study, with an anticipated target of 150 patients in the first four years of the budgeted study period. Under the local direction of Dr. Kumaresan, the site study personnel will follow procedures laid out in the study protocol and communicate with Dr. Johnson-Akeju's team at Massachusetts General Hospital (MGH) for any issues. Dr. Kumaresan will also provide scientific expertise in the conduct of clinical trials in patients undergoing cardiac surgery, and will assist with analysis/interpretation of results, as needed. Cedars-Sinai Medical Center will screen, enroll, collect data, perform neurocognitive assessments, evaluate for and report adverse events, review documentation and reporting of research activities, and communicate to the study coordinating center at MGH. Site investigators at Cedars-Sinai Medical Center will maintain the initial recruitment documentation (informed consent, patient information) and collect all relevant study data, including biospecimens. The Cedars-Sinai Medical Center MINDDS II study research team will participate in network calls, data review, and discussion as the study progresses. Cedars-Sinai Medical Center will obtain permission to cede review to the Mass General Brigham Institutional Review Board for all study conduct and regulatory oversight. Dr. Kumaresan will also be responsible for maintaining other mandatory clinical trials trainings for their site, as indicated. Throughout the study, investigators at Cedars-Sinai Medical Center will assure compliance with human subjects research regulations and ensure complete and timely communication with the MGH coordinating center. As the study progresses, Dr. Kumaresan will participate in data review, discussion, and manuscript preparations. Cedars-Sinai Medical Center
Project Grant R01AG083777 $514.0k 6/9/26 GR0245766S11S
Vanderbilt University Medical Center will serve as an enrolling site for the proposed study, with an anticipated target of 150 patients in the first four years of the budgeted study period. Under the local direction of Dr. Frederic Billings, the site study personnel will follow procedures laid out in the study protocol and communicate with Dr. Johnson-AkejuAca'a"cs team at Massachusetts General Hospital (MGH) for any issues. Dr. Frederic Billings will also provide scientific expertise in the conduct of clinical trials in patients undergoing cardiac surgery, and will assist with analysis/interpretation of results, as needed. Vanderbilt University Medical Center will screen, enroll, collect data, perform neurocognitive assessments, evaluate for and report adverse events, review documentation and reporting of research activities, and communicate to the study coordinating center at MGH. Site investigators at Vanderbilt University Medical Center will maintain the initial recruitment documentation (informed consent, patient information) and collect all relevant study data, including biospecimens. The Vanderbilt University Medical Center MINDDS II study research team will participate in network calls, data review, and discussion as the study progresses. Vanderbilt University Medical Center will obtain permission to cede review to the Mass General Brigham Institutional Review Board for all study conduct and regulatory oversight. Dr. Frederic Billings will also be responsible for maintaining other mandatory clinical trials trainings for their site, as indicated. Throughout the study, investigators at Vanderbilt University Medical Center will assure compliance with human subjects research regulations and ensure complete and timely communication with the MGH coordinating center. As the study progresses, Dr. Frederic Billings will participate in data review, discussion, and manuscript preparations. Protocol: The Protocol, Aca'A"Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS II) Aca'i is incorporated to this Agreement by reference and sent under separate cover to Subrecipient and Subrecipient Investigator. Vanderbilt University Medical Center
Project Grant R01AG083777 $834.7k 4/28/26 GR0245766S13S
The Regents of the University of California, San Francisco ("UCSF") will serve as an enrolling site for the proposed study, with an anticipated target of 150 patients in the first four years of the budgeted study period. Under the local direction of Dr. Matthieu Legrand, the site study personnel will follow procedures laid out in the study protocol and communicate with Dr. Johnson-Akeju's team at Massachusetts General Hospital (MGH) for any issues. Dr. Matthieu Legrand will also provide scientific expertise in the conduct of clinical trials in patients undergoing cardiac surgery, and will assist with analysis/interpretation of results, as needed. UCSF will screen, enroll, collect data, perform neurocognitive assessments, evaluate for and report adverse events, review documentation and reporting of research activities, and communicate to the study coordinating center at MGH. Site investigators at UCSF will maintain the initial recruitment documentation (informed consent, patient information) and collect all relevant study data, including biospecimens. The UCSF MINDDS II study research team will participate in network calls, data review, and discussion as the study progresses. UCSF will obtain permission to cede review to the Mass General Brigham Institutional Review Board for all study conduct and regulatory oversight. Dr. Matthieu Legrand will also be responsible for maintaining other mandatory clinical trials trainings for their site, as indicated. Throughout the study, investigators at UCSF will assure compliance with human subjects research regulations and ensure complete and timely communication with the MGH coordinating center. As the study progresses, Dr. Matthieu Legrand will participate in data review, discussion, and manuscript preparations. The Regents Of The University Of California. San Francisco
Project Grant R01AG083777 $477.2k 1/15/26 GR0245766S08S
Albert Einstein College of Medicine/Montefiore Medical Center will serve as an enrolling site for the proposed study, with an anticipated target of 150 patients in the first four years of the budgeted study period. Under the local direction of Dr. Matthias Eikermann, the site study personnel will follow procedures laid out in the study protocol and communicate with Dr. Johnson-Akeju's team at Massachusetts General Hospital (MGH) for any issues. Dr. Eikermann will also provide scientific expertise in the conduct of clinical trials in patients undergoing cardiac surgery, and will assist with analysis/interpretation of results, as needed. Albert Einstein College of Medicine/Montefiore Medical Center will screen, enroll, collect data, perform neurocognitive assessments, evaluate for and report adverse events, review documentation and reporting of research activities, and communicate to the study coordinating center at MGH. Site investigators at Albert Einstein College of Medicine/Montefiore Medical Center will maintain the initial recruitment documentation (informed consent, patient information) and collect all relevant study data, including biospecimens. The Albert Einstein College of Medicine/Montefiore Medical Center MINDDS II study research team will participate in network calls, data review, and discussion as the study progresses. Albert Einstein College of Medicine/Montefiore Medical Center will obtain permission to cede review to the Mass General Brigham Institutional Review Board for all study conduct and regulatory oversight. Dr. Eikermann will also be responsible for maintaining other mandatory clinical trials trainings for their site, as indicated. Throughout the study, investigators at Albert Einstein College of Medicine/Montefiore Medical Center will assure compliance with human subjects research regulations and ensure complete and timely communication with the MGH coordinating center. As the study progresses, Dr. Eikermann will participate in data review, discussion, and manuscript preparations. Albert Einstein College of Medicine/Montefiore Medical Center will screen, enroll, collect data, perform neurocognitive assessments, evaluate for and report adverse events, review documentation and reporting of research activities, and communicate to the study coordinating center at MGH. Site investigators at Albert Einstein College of Medicine/Montefiore Medical Center will maintain the initial recruitment documentation (informed consent, patient information) and collect all relevant study data, including biospecimens. The Albert Einstein College of Medicine/Montefiore Medical Center MINDDS II study research team will participate in network calls, data review, and discussion as the study progresses. Albert Einstein College of Medicine/Montefiore Medical Center will obtain permission to cede review to the Mass General Brigham Institutional Review Board for all study conduct and regulatory oversight. Dr. Eikermann will also be responsible for maintaining other mandatory clinical trials trainings for their site, as indicated. Throughout the study, investigators at Albert Einstein College of Medicine/Montefiore Medical Center will assure compliance with human subjects research regulations and ensure complete and timely communication with the MGH coordinating center. As the study progresses, Dr. Eikermann will participate in data review, discussion, and manuscript preparations. Protocol: The Protocol, Aca'A"Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS II)Aca'i is incorporated to this Agreement by reference and sent under separate cover to Subrecipient and Subrecipient Investigator. Albert Einstein College Of Medicine
Project Grant R01AG083777 $488.9k 8/28/25 GR0245766S09S
Duke University School of Medicine will serve as an enrolling site for the proposed study, with an anticipated target of 150 patients in the first four years of the budgeted study period. Under the local direction of Dr. Podgoreanu, the site study personnel will follow procedures laid out in the study protocol and communicate with Dr. Johnson-AkejuAca'a"cs team at Massachusetts General Hospital (MGH) for any issues. Dr. PodgoreanuI will also provide scientific expertise in the conduct of clinical trials in patients undergoing cardiac surgery, and will assist with analysis/interpretation of results, as needed. Duke University School of Medicine will screen, enroll, collect data, perform neurocognitive assessments, evaluate for and report adverse events, review documentation and reporting of research activities, and communicate to the study coordinating center at MGH. Site investigators at Duke University School of Medicine will maintain the initial recruitment documentation (informed consent, patient information) and collect all relevant study data, including biospecimens. The Duke University School of Medicine MINDDS II study research team will participate in network calls, data review, and discussion as the study progresses. Duke University School of Medicine will obtain permission to cede review to the Mass General Brigham Institutional Review Board for all study conduct and regulatory oversight. Dr. Podgoreanu will also be responsible for maintaining other mandatory clinical trials trainings for their site, as indicated. Throughout the study, investigators at Duke University School of Medicine will assure compliance with human subjects research regulations and ensure complete and timely communication with the MGH coordinating center. As the study progresses, Dr. Podgoreanu will participate in data review, discussion, and manuscript preparations. Protocol: The Protocol, Aca'A"Minimizing ICU Neurological Dysfunction with Dexmedetomidine-induced Sleep (MINDDS II)Aca'i is incorporated to this Agreement by reference and sent under separate cover to Subrecipient and Subrecipient Investigator. Duke University
Project Grant R01AG083777 $468.5k 8/28/25